Andy Minke joined OncoNano in February 2022 as Senior Director of Project & Program Management. Andy brings extensive experience in global drug and device development and commercialization working at Galderma, Alcon, and Bausch + Lomb. Most recently, Andy was Director of Project Management at Immunovant, a clinical-stage biopharmaceutical company, where he led multiple pivotal development projects of Immunovant’s investigational therapy candidate, batoclimab. Prior to Immunovant, he held multiple roles at Galderma including Head of Global Project Management for the Prescription Medicine business unit, where he was instrumental in reshaping project management to drive Galderma’s investigational therapy candidate, nemolizumab, for atopic dermatitis, prurigo nodularis and chronic kidney disease-associated pruritus. During his 20+-year career, Andy held various roles with increasing responsibility in Project Management, Regulatory Affairs, Quality Operations and Procurement. Andy holds a bachelor’s degree from Zuyd University of Applied Sciences in the Netherlands and a M.B.A from Harrison College of Business at Southeast Missouri State University.